MA54541A - Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées - Google Patents

Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées

Info

Publication number
MA54541A
MA54541A MA054541A MA54541A MA54541A MA 54541 A MA54541 A MA 54541A MA 054541 A MA054541 A MA 054541A MA 54541 A MA54541 A MA 54541A MA 54541 A MA54541 A MA 54541A
Authority
MA
Morocco
Prior art keywords
crystalline
pharmaceutical compositions
organic compound
salt forms
related pharmaceutical
Prior art date
Application number
MA054541A
Other languages
English (en)
Inventor
Syed Altaf
Abira Ramakrishnan
Jacob Sizemore
Shijie Zhang
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA54541A publication Critical patent/MA54541A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054541A 2018-12-21 2019-12-20 Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées MA54541A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05

Publications (1)

Publication Number Publication Date
MA54541A true MA54541A (fr) 2022-03-09

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054541A MA54541A (fr) 2018-12-21 2019-12-20 Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées

Country Status (23)

Country Link
US (2) US12297179B2 (fr)
EP (1) EP3898597A1 (fr)
JP (3) JP2022515239A (fr)
KR (1) KR20220035022A (fr)
CN (1) CN113508108B (fr)
AU (1) AU2019403396B2 (fr)
BR (1) BR112021012305A2 (fr)
CA (1) CA3124401A1 (fr)
CL (1) CL2021001640A1 (fr)
CO (1) CO2021009309A2 (fr)
CR (1) CR20210394A (fr)
GE (2) GEP20247683B (fr)
IL (1) IL284218B1 (fr)
JO (1) JOP20210147A1 (fr)
MA (1) MA54541A (fr)
MX (1) MX2021007536A (fr)
NI (1) NI202100055A (fr)
PE (2) PE20212197A1 (fr)
PH (1) PH12021551495A1 (fr)
SG (1) SG11202106526UA (fr)
TW (1) TWI875727B (fr)
UA (1) UA130491C2 (fr)
WO (1) WO2020132471A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110662539B (zh) 2017-04-24 2023-08-15 奥里吉恩探索技术有限公司 三取代的苯并三唑衍生物作为二氢乳清酸加氧酶抑制剂的使用方法
EP3755324B1 (fr) 2018-02-20 2025-07-30 Les Laboratoires Servier Utilisation d'un dérivé de benzotriazole dans le traitement de double et triple hit lymphome diffus à grandes cellules b
JP7734742B2 (ja) * 2020-08-27 2025-09-05 レ ラボラトワール セルビエ 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用
WO2025227007A1 (fr) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Méthodes et compositions pour inhiber la dihydroorotate déshydrogénase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7622000A (en) * 1999-10-01 2001-05-10 Institute Of Molecular And Cell Biology Compounds for the treatment of viral-mediated diseases
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
JP2011515410A (ja) * 2008-03-19 2011-05-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 塩の形のｍＴＯＲ阻害剤
EP2228367A1 (fr) * 2009-03-13 2010-09-15 Almirall, S.A. Sels adjuvants d'amines contenant des groupes hydroxyle et/ou carbonyle avec des dérivés d'acides aminonicotiques en tant qu'inhibiteurs de la DHODH
EP2230232A1 (fr) 2009-03-13 2010-09-22 Almirall, S.A. Sels adjuvants de trométhamine dotés de dérivés d'acide azabiphénylaminobenzoïque en tant qu'inhibiteurs de la DHOD
EA024026B1 (ru) 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
RS57962B1 (sr) * 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
EP3755324B1 (fr) 2018-02-20 2025-07-30 Les Laboratoires Servier Utilisation d'un dérivé de benzotriazole dans le traitement de double et triple hit lymphome diffus à grandes cellules b
WO2021262881A1 (fr) * 2020-06-24 2021-12-30 Servier Pharmaceuticals, Llc Utilisation d'un composé inhibiteur de dhodh en polythérapie anticancéreuse
JP7734742B2 (ja) * 2020-08-27 2025-09-05 レ ラボラトワール セルビエ 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用

Also Published As

Publication number Publication date
PH12021551495A1 (en) 2022-03-07
AU2019403396A1 (en) 2021-07-08
WO2020132471A8 (fr) 2020-08-06
CA3124401A1 (fr) 2020-06-25
NI202100055A (es) 2021-12-01
US20220055995A1 (en) 2022-02-24
PE20260309A1 (es) 2026-02-11
MX2021007536A (es) 2021-09-23
PE20212197A1 (es) 2021-11-16
US20250270175A1 (en) 2025-08-28
AU2019403396B2 (en) 2024-12-12
JP2024161431A (ja) 2024-11-19
TWI875727B (zh) 2025-03-11
UA130491C2 (uk) 2026-03-04
GEP20247683B (en) 2024-10-28
JOP20210147A1 (ar) 2023-01-30
JP2026001058A (ja) 2026-01-06
JP2022515239A (ja) 2022-02-17
CN113508108B (zh) 2024-12-24
IL284218B1 (en) 2026-01-01
TW202039448A (zh) 2020-11-01
JP7749080B2 (ja) 2025-10-03
GEAP202415700A (en) 2024-05-13
CR20210394A (es) 2021-12-13
BR112021012305A2 (pt) 2021-10-05
IL284218A (en) 2021-08-31
US12297179B2 (en) 2025-05-13
SG11202106526UA (en) 2021-07-29
WO2020132471A1 (fr) 2020-06-25
CO2021009309A2 (es) 2021-10-29
EP3898597A1 (fr) 2021-10-27
CN113508108A (zh) 2021-10-15
KR20220035022A (ko) 2022-03-21
CL2021001640A1 (es) 2022-06-03

Similar Documents

Publication Publication Date Title
MA54541A (fr) Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
EP3870178A4 (fr) Formes cristallines d'inhibiteurs de mnk
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
EP3924352A4 (fr) Formes cristallines d'un inhibiteur rsk
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
CL2008002241A1 (es) Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
EP4263488A4 (fr) Formes solides d'un composé
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EP3897660A4 (fr) Nouvelles formes cristallines d'un composé de nrtti
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
EP3819299A4 (fr) Composé d'hypoxanthine
EP3808747A4 (fr) Composé d'imidazopyridinone
CO2020011860A2 (es) Compuestos de 4–metildihidropirimidinona y su uso farmacéutico
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
EP3925672A4 (fr) Composition contenant un sel d'ammonium organique
EP4015002A4 (fr) Composition pharmaceutique orale contenant un composé hétérocyclique
EP3849964A4 (fr) Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate
EP3672972A4 (fr) Sels et formes cristallines d'un composé